Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma.
about
Reactive Oxygen Species Regulate T Cell Immune Response in the Tumor MicroenvironmentMolecular Imaging of Immunotherapy Targets in Cancer.A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status.Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics.
P2860
Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pembrolizumab: a novel antipro ...... atment of metastatic melanoma.
@en
type
label
Pembrolizumab: a novel antipro ...... atment of metastatic melanoma.
@en
prefLabel
Pembrolizumab: a novel antipro ...... atment of metastatic melanoma.
@en
P2860
P356
P1476
Pembrolizumab: a novel antipro ...... atment of metastatic melanoma.
@en
P2860
P356
10.1111/JCPT.12304
P577
2015-06-29T00:00:00Z